sh-Polypeptide-59 for Hair Regrowth
Evidence Review created on 11/08/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: SH-Polypeptide-59, Platelet-Derived Growth Factor Beta Polypeptide, PDGF-B, PDGF-BB, PDGF-2, PDGFB, rhPDGF-BB, Pure PDGF
Motivation
sh-Polypeptide-59 is the cosmetic ingredient name for a lab-made copy of human platelet-derived growth factor B, a signaling protein that blood platelets release to start tissue repair. It is produced in bacteria and added to scalp serums and post-procedure skin products marketed for fuller hair and better-looking skin. Interest rests on the idea that the same repair signal might wake resting hair follicles.
The protein is not new to medicine. A nearly identical version made in yeast has long been sold as a prescription gel for slow-healing foot wounds, and the growth factor is one of the ingredients credited for the popularity of injected platelet concentrates in hair clinics. It now appears in serums sold to people focused on longevity, where a full head of hair is treated as one visible sign of how a person is aging.
This review examines what is known about sh-Polypeptide-59 for hair regrowth: whether human evidence exists for the ingredient itself, how much can be borrowed from the related wound drug and from platelet injections, and which safety questions matter for a health-focused adult applying it to the scalp.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
Overview-level reading on sh-Polypeptide-59, its parent protein, and the cosmetic growth-factor category it belongs to.
-
Recombinant Platelet-Derived Growth Factor-BB vs Platelet-Rich Plasma in Aesthetic and Regenerative Medicine: Mechanistic Standardization vs Biologic Heterogeneity - Gould et al., 2026
A structured narrative review contrasting pure PDGF-BB (two B chains of platelet-derived growth factor, PDGF, the repair protein sh-Polypeptide-59 copies) with platelet-rich plasma, including follicle biology and evidence gaps.
-
Safety of Exogenous Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) for Medical and Cosmetic Applications: A Review - Hee et al., 2026
Identifies sh-Polypeptide-59 as the cosmetic name of recombinant human PDGF-BB (rhPDGF-BB) and compiles its safety and absorption data; all authors work for or consult for Lynch Regenerative Medicine, sponsor of studies of a PDGF-BB cosmetic.
-
Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: risk or fraud? - Martínez-Carpio, 2023
Critiques sh-Oligopeptide-1, a synthetic epidermal growth factor copy from the same synthetic-human growth-factor category as sh-Polypeptide-59, arguing that such cosmetic copies lack proven bioactivity and carry unknown long-term risk.
Only three items are listed because no further overview-level source discusses sh-Polypeptide-59 or topical PDGF for hair in depth. None of the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has published content on sh-Polypeptide-59 or PDGF for hair; Attia (Attia AMA #63) and Huberman (Huberman Lab hair episode) mention platelet-rich plasma only inside broader hair-loss episodes, without discussing PDGF.
Grokipedia
-
Covers the PDGF-B protein that sh-Polypeptide-59 copies: receptor signaling, roles in wound repair and blood-vessel growth, and the gene fusion with COL1A1 (the type I collagen gene) behind a rare skin sarcoma (connective-tissue cancer).
Examine
No Examine article on sh-Polypeptide-59 exists; Examine.com also has no entry for platelet-derived growth factor, consistent with its focus on supplements rather than cosmetic proteins.
ConsumerLab
No ConsumerLab article on sh-Polypeptide-59 exists; the site search returned only unrelated recall notices and news releases.
Systematic Reviews
Systematic reviews of recombinant PDGF-BB, the protein sh-Polypeptide-59 copies, cover its wound and dental uses; none addresses hair.
-
Growth factors for treating diabetic foot ulcers - Martí-Carvajal et al., 2015
Pools 28 trials of 11 growth factors for diabetic foot ulcers; becaplermin, a yeast-made recombinant PDGF-BB, raised complete healing. It does not address hair.
-
Efficacy of topical recombinant human platelet-derived growth factor for treatment of diabetic lower-extremity ulcers: Systematic review and meta-analysis - Zhao et al., 2014
Pools six randomized trials (992 patients) of topical rhPDGF-BB gel for diabetic ulcers; complete healing rose versus placebo or standard care. Hair is not addressed.
-
Recombinant Human Platelet-Derived Growth Factor: A Systematic Review of Clinical Findings in Oral Regenerative Procedures - Tavelli et al., 2021
Covers 63 human studies of rhPDGF-BB in dental bone and gum regeneration; none reported serious adverse effects. It does not address hair or cancer.
Neither the claimed hair effect nor the principal risk (the cancer signal of the related drug becaplermin) is represented by a systematic review or meta-analysis of sh-Polypeptide-59 or recombinant PDGF-BB.
Mechanism of Action
sh-Polypeptide-59 is a synthetic copy of the human PDGF-B chain produced in Escherichia coli (EU CosIng entry). Two B chains form PDGF-BB; the drug version, becaplermin, is a homodimer (two identical chains) of about 25 kDa (kilodaltons, a unit of molecular mass) (Regranex label, issued by its current labeler, LRM Therapeutics).
- Receptors and selectivity: PDGF-BB activates both PDGF receptor types, PDGFRα and PDGFRβ (cell-surface tyrosine kinases, enzymes that switch on growth signals). Human dermal papilla cells (the signaling cells at the follicle base) carry PDGFRβ, and follicular keratinocytes (hair-forming cells) carry both (Kamp 2003).
- Proposed hair effect: Injected PDGF-BB pushed resting mouse follicles into anagen (the growth phase) and raised Lef-1 and Wnt5a, members of the Wnt pathway (a follicle-growth switch) (Tomita 2006). PDGF signaling also maintains follicle dermal stem cells in mice (González 2017).
- Pharmacokinetics: A review of animal studies reports a systemic half-life of 2–55 minutes; the protein is cleared by receptor uptake and breakdown inside cells and is trapped by α2-macroglobulin (a blood protein that binds growth factors) (Hee 2026, a review written by employees and a consultant of Lynch Regenerative Medicine, which sponsors studies of a PDGF-BB cosmetic, NCT07718347). Daily gel on ulcers produced no consistent rise in blood PDGF (Regranex label).
- Competing view: Molecules above about 500 daltons generally fail to cross intact skin (Bos 2000), so a 25 kDa protein on unbroken scalp may never reach the follicle. In platelet injections, PDGF content did not track hair response (Rodrigues 2019).
Historical Context & Evolution
- Original use: PDGF was first described as the platelet factor that drives fibroblasts (connective-tissue cells) and smooth muscle cells to divide during repair. Its yeast-made recombinant form, becaplermin, is approved in the US as Regranex gel for diabetic lower-extremity ulcers (Regranex label); PDGF-BB products for dental and bone-graft surgery followed, as a manufacturer-authored review describes (Hee 2026).
- Path to hair: Mouse work showed PDGF-BB injections start the follicle growth phase (Tomita 2006), and PDGF from immature fat-lineage cells was implicated in activating follicle stem cells (Festa 2011). In parallel, platelet-rich plasma (PRP, a concentrate of the patient’s own platelets) became a popular injected hair treatment; platelet products deliver PDGF-BB among other growth factors (Cole 2017).
- Cosmetic era: The EU inventory lists sh-Polypeptide-59 as a skin-conditioning ingredient (EU CosIng entry). Pure PDGF-BB is now sold for post-procedure skin care, according to the same review (Hee 2026), and longevity-branded scalp serums list it (Perfect Hair Health review).
- Shifting safety view: Trial follow-up and one claims cohort raised a cancer signal for becaplermin; two later Veterans Affairs cohorts found no excess cancer mortality, and the label now presents both findings (Regranex label). The question remains open rather than settled in either direction.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: no human trial has tested sh-Polypeptide-59 or isolated PDGF-BB on hair, and the controlled human hair data come only from injected platelet mixtures.
Medium 🟩 🟩
Post-Procedure Facial Skin Recovery ⭕️ Not Central to Hair Regrowth
Topical pure PDGF-BB (300 µg/mL) applied after radiofrequency microneedling (needling combined with radiofrequency heating) improved blinded aesthetic ratings of facial skin at 30 days versus an emollient in a 12-woman randomized trial run by the maker, Lynch Regenerative Medicine (Lynch 2025). This bears on skin recovery after cosmetic procedures, not on hair. It is a single small trial from one research group.
Magnitude: About 1 point better than the emollient group on a 5-point blinded global aesthetic improvement scale at day 30, in 8 versus 4 participants; no confidence interval reported (Lynch 2025).
Low 🟩
Hair Density Gain with PDGF-Containing Platelet Injections ⚠️ Conflicted
Injected PRP releases PDGF alongside many other factors, so this evidence is indirect (mixture, injection). A meta-analysis of randomized controlled trials (RCTs) found more hair than placebo (Kieling 2024); a female RCT found no difference (Puig 2016). Net: platelet injections modestly help; PDGF’s share is unproven.
Magnitude: 27.55 hairs/cm² more than placebo (95% CI 14.04 to 41.06; CI, confidence interval, is the range likely to contain the true value) across 13 trials of injected PRP, rated low-quality evidence (Kieling 2024); this is not a figure for sh-Polypeptide-59.
Ulcer Healing ⭕️ Not Central to Hair Regrowth ⚠️ Conflicted
Becaplermin (yeast-made PDGF-BB) is approved for diabetic foot ulcers (Regranex label); this bears on skin repair, not hair, and is indirect (drug gel, open wounds). A 382-patient manufacturer-linked RCT raised complete closure (Wieman 1998); a 250-patient trial found no significant difference (Regranex label). Net: modest benefit on open ulcers.
Magnitude: Complete closure 43% more frequent than with placebo gel (50% vs 35%) within 20 weeks (Wieman 1998).
Oral Tissue Regeneration ⭕️ Not Central to Hair Regrowth
rhPDGF-BB placed with bone grafts aids regrowth of bone and gum around teeth; this bears on oral repair, not hair, and is indirect (surgical implant). A systematic review of 63 studies found benefit without serious adverse effects (Tavelli 2021); a meta-analysis found more bone fill in defects (Khoshkam 2015).
Magnitude: 0.95 mm more linear defect fill (new bone height in the defect) than the carrier alone (95% CI 0.62 to 1.28), pooled from the rhPDGF-BB studies of a seven-study meta-analysis of bone loss around teeth that also covered another growth factor (Khoshkam 2015); this is not a figure for hair.
Speculative 🟨
Anagen Induction and Follicle Stem-Cell Support
Injected PDGF-BB started growth in resting mouse follicles (Tomita 2006) and expanded mouse follicle stem cells and human skin precursors (González 2017). No human hair studies exist; evidence is animal and cell work only.
Benefit-Modifying Factors
- Genetic variation: No known polymorphism changes response. A trial protocol by Lynch Regenerative Medicine–funded investigators cites a genetic association study linking a PDGFRB (PDGF receptor β gene) variant that lowers receptor levels with more chronic skin ulcers (Clark 2026); untested for hair.
- Baseline biomarkers: No blood or scalp marker predicts response. In a placebo-controlled platelet-injection trial, PDGF content of the injected plasma did not correlate with hair gains (Rodrigues 2019).
- Sex: No sex-specific data exist for sh-Polypeptide-59. Platelet injections raised hair counts in a male trial (Rodrigues 2019) but not in a female trial (Puig 2016), so any growth-factor benefit may differ by sex.
- Type of hair loss: Androgenetic alopecia (hormone-driven pattern hair loss) is driven by dihydrotestosterone (DHT, a potent testosterone derivative), which PDGF does not block. Scarring alopecias destroy follicles, leaving little to stimulate; stress-triggered shedding often resolves alone, confusing attribution.
- Age: Older scalps carry more shrunken follicles and a thinner fat layer, and mouse work ties fat-lineage PDGF to follicle activation (Festa 2011). Whether added PDGF offsets age-related losses is untested in people over 60.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: no adverse event has been shown in trials from more than one independent research group, since the ingredient’s own trials are small manufacturer-run studies on facial skin after procedures and the larger controlled safety data come from one drug gel used on open ulcers.
Medium 🟥 🟥
No risk reaches Medium: the ingredient’s own small randomized trial on microneedled facial skin reported no adverse reactions (Lynch 2025), and the harms seen with becaplermin come from a drug gel on open diabetic ulcers, a different formulation and route than a cosmetic on intact scalp.
Low 🟥
Application-Site Irritation and Sensitization ⚠️ Conflicted
Becaplermin gel on ulcers (indirect: drug gel, open wounds) was followed by slightly more rash than placebo among patients with suspected wound infections in a pooled analysis by the manufacturer’s research institute (Smiell 1998). A placebo-controlled RCT found similar adverse events (Wieman 1998). Net: rash is rare and possibly vehicle-related.
Magnitude: Erythematous rash (red skin rash) in 2% with becaplermin gel versus 1% with placebo gel among patients with suspected wound infections, and none with ulcer care alone (Smiell 1998).
Cancer Distant from the Application Site ⚠️ Conflicted
Becaplermin (indirect: drug gel, open wounds) carries a label cancer warning (Regranex label). A manufacturer-sponsored claims cohort saw more cancer deaths with three or more tubes, no longer significant after follow-up through 2006 (Ziyadeh 2011); two Veterans Affairs cohorts found no excess (Regranex label). Net: no consistent excess.
Magnitude: Cancer in 2.7% with becaplermin versus 1% with vehicle over a median of about 20 months, relative risk (ratio of event rates) 2.7 (95% CI 0.6–12.8) (Regranex label); in a Veterans Affairs cohort of 6,429 per group, 197 versus 206 cancer deaths, cancer-mortality hazard ratio (ratio of event rates over time) 0.9 (95% CI 0.8–1.2) (Regranex label).
Granulomas When Delivered by Microneedling
Microneedling (rolling or stamping fine needles into the skin), often paired with growth-factor serums, drives topical products into the dermis (the skin layer beneath the surface). Three women developed facial foreign-body granulomas (persistent inflammatory nodules) after microneedling with a cosmetic serum (Soltani-Arabshahi 2014). No case involved sh-Polypeptide-59.
Magnitude: Not quantified in available studies. Only case reports exist, and no study has measured how often granulomas follow microneedled serums.
Speculative 🟨
Fibrotic Signaling in Scarring Hair Loss
PDGF drives fibroblast growth, and PDGF expression is raised in scalp affected by central centrifugal cicatricial alopecia (a scarring hair loss) (Aguh 2018). Whether added PDGF-BB worsens scarring is untested; the basis is mechanistic only.
Local Proliferative Overstimulation
A fused COL1A1-PDGFB gene drives dermatofibrosarcoma protuberans (a rare skin sarcoma) through constant PDGF-B signaling, as a genetics review describes (Sirvent 2003). Topical exposure is far lower and transient; the basis is mechanistic only.
Risk-Modifying Factors
- Genetic variation: No inherited variant is known to raise risk from topical PDGF-BB. The COL1A1-PDGFB fusion of dermatofibrosarcoma protuberans arises within the tumor, per a genetics review (Sirvent 2003); a history of that tumor makes added PDGF signaling an inferred concern.
- Baseline biomarkers: No laboratory marker predicts harm. The relevant baseline check is a scalp skin examination, because the becaplermin label contraindicates use on known neoplasms (abnormal tissue growths, including tumors) at the application site (Regranex label).
- Sex: No sex difference in adverse events is reported for becaplermin. Pregnancy lacks any human data, and no animal reproduction studies were done (Regranex label).
- Pre-existing conditions: Known cancer calls for careful benefit-risk weighing on the becaplermin label (Regranex label); scarring alopecia shows raised PDGF expression (Aguh 2018); eczema, psoriasis or a microneedled scalp increase penetration (inferred from barrier loss).
- Age: Older adults carry more sun-damaged scalp skin and more background skin cancer. Becaplermin trials included 150 people aged 65 or older without safety differences, but too few over 75 to judge (Regranex label).
Key Interactions & Contraindications
Documented interactions:
- None identified
Theoretical interactions (inferred from mechanism, not studied in humans):
-
Microneedling (procedure): Needling pushes topical product into the dermis; case reports with other cosmetic serums describe foreign-body granulomas and systemic hypersensitivity (Soltani-Arabshahi 2014). Consequence: persistent nodules. Mitigation: restricting needling to sterile products made for intradermal contact.
- PDGF receptor tyrosine kinase inhibitors (imatinib, sunitinib, nintedanib): These prescription drugs block the receptor enzyme PDGF-BB activates. Consequence: any hair effect would be expected to disappear. Mitigation: none needed for safety; no benefit is expected during their use.
- Topical minoxidil (OTC, over-the-counter): Both are proposed to prolong the growth phase, so effects could add. Consequence: more vehicle irritation from layered products. Mitigation: application at separate times of day.
- Topical retinoids (vitamin A–derived skin drugs: tretinoin; OTC adapalene) and salicylic acid: Barrier thinning would increase protein penetration. Consequence: more irritation and dermal exposure. Mitigation: alternate-day use rather than layering.
- Topical corticosteroids (anti-inflammatory steroid creams: OTC hydrocortisone; prescription clobetasol): These suppress repair signaling. Consequence: a possible blunted effect. Mitigation: separating the two in site or time.
- Finasteride and dutasteride: These prescription drugs lower DHT, a separate pathway. Consequence: none expected beyond each drug’s own effects. Mitigation: none needed.
- Copper tripeptide-1 (GHK-Cu) and other synthetic growth-factor peptides (sh-Oligopeptide-1, sh-Polypeptide-9): These cosmetic supplements add repair and blood-vessel signaling. Consequence: unknown cumulative proliferative stimulation. Mitigation: fewer stacked growth-factor products.
- Oral hair supplements (biotin, iron, saw palmetto): These act on separate pathways (nutrient repletion, androgen metabolism). Consequence: none expected. Mitigation: none needed.
- PRP injections: Platelets add their own PDGF. Consequence: additive local PDGF exposure of unknown effect. Mitigation: a 24-hour gap between injection and serum application.
Populations who should avoid sh-Polypeptide-59:
- People with a known skin cancer or other neoplasm on the scalp area to be treated: becaplermin is contraindicated on neoplasms at the application site (Regranex label).
- People with known cancer elsewhere: the becaplermin label calls for careful benefit-risk evaluation in known malignancy (Regranex label).
- Pregnant or breastfeeding individuals: inferred from the cell-proliferation and blood-vessel-growth activity the becaplermin label attributes to PDGF-BB, with no human or animal reproduction data on that label (Regranex label); no human data.
- People with scarring alopecia: inferred from raised PDGF expression in affected scalp (Aguh 2018); no human data on added PDGF.
- People sensitized to product preservatives: the becaplermin label names parabens or m-cresol as possible causes of application-site sensitization (Regranex label).
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Scalp skin check before starting: A scalp examination for new, changing or bleeding lesions, with no application on any lesion, prevents the use on neoplasms that the becaplermin label contraindicates (Regranex label).
- Patch test: Application behind one ear once daily for 3–5 days before scalp use detects irritation or sensitization on a small area first.
- Interruption on site reactions: The becaplermin label calls for interruption and possible patch testing when application-site reactions occur, limiting sensitization from preservatives (Regranex label).
- Sterile products for microneedling: Pairing needling only with sterile products intended for intradermal use, at a home needle depth of 0.5 mm or less, reduces the risk of granulomas and infection.
- One growth-factor product at a time: Avoiding stacked growth-factor serums limits cumulative proliferative stimulation and the theoretical cancer and scarring concerns.
- Annual skin examination: A yearly dermatologist skin check during long-term use, especially after prior skin cancer, catches new scalp lesions early.
- Defined trial period: Reassessment at 6 months with standardized photographs, and stopping without a measurable gain, limits open-ended exposure to an unproven product.
Therapeutic Protocol
Parameters without a citation (timing, frequency, duration, technique) reflect common practice.
- No established hair dose: No trial defines a dose of sh-Polypeptide-59 for hair, and the reviewed Blueprint serum does not disclose its active concentrations (Perfect Hair Health review).
- Drug reference dose: Becaplermin gel contains 100 µg/g and is applied once daily for up to 20 weeks on ulcers (Regranex label).
- Aesthetic reference dose (Lynch Regenerative Medicine): Ariessence pure PDGF+ contains 0.3 mg/mL PDGF-BB, 0.150 mg per one-time post-procedure application, per a manufacturer-authored review (Hee 2026).
- Consumer serum approach (Bryan Johnson’s Blueprint): The serum is applied to a dry scalp morning or night, after a peptide shampoo (Perfect Hair Health review).
- Clinic approach: Growth-factor serums are applied right after scalp microneedling; the tested scaffold is weekly microneedling with minoxidil (Dhurat 2013), never tested with sh-Polypeptide-59.
- Platelet-injection alternative: PRP delivers PDGF with other factors; one placebo-controlled trial used four scalp injections (Rodrigues 2019).
- Time of day: No data favor a time; evening application to a washed scalp leaves product in place for hours, echoing becaplermin’s roughly 12-hour contact (Regranex label).
- Half-life: A review reports a systemic half-life of 2–55 minutes in animals (Hee 2026); daily topical gel produced no consistent blood rise (Regranex label).
- Single or split dosing: Once-daily single application mirrors the becaplermin schedule; no data support splitting.
- Genetic polymorphisms: No variant is known to change dose or response; no pharmacogenetic testing applies.
- Sex: No sex-specific dosing exists; platelet-injection data differ between male and female trials, so women may see less benefit.
- Age: No age-specific dosing exists; skin-cancer rates rise with age, which makes the baseline scalp skin examination more relevant in older adults.
- Baseline biomarkers: No marker guides dose; PDGF content of platelet injections did not predict response (Rodrigues 2019).
- Pre-existing conditions: In androgenetic alopecia, PDGF leaves the DHT pathway untouched, so practitioners pair growth-factor products with established hair-loss drugs rather than replacing them.
Discontinuation & Cycling
- Short-term or ongoing: No defined course exists. Any hair effect from a growth-phase signal would likely need ongoing use, as with other non-surgical hair treatments.
- Withdrawal effects: None are described; the becaplermin label lists no withdrawal reactions (Regranex label).
- Tapering: Not needed; no dependence or rebound mechanism is known, so use can stop at once.
- Cycling: No data show that cycling maintains efficacy. The becaplermin label sets no exposure limit; it calls for reassessment if an ulcer has not healed within 20 weeks (Regranex label).
- Stop triggers: A new or changing scalp lesion, persistent irritation, pregnancy, or a cancer diagnosis.
Sourcing and Quality
- Ingredient identity: “sh-Polypeptide-59” on an ingredient list designates synthetic PDGF-B made in Escherichia coli (EU CosIng entry); labels rarely state concentration or biological activity.
- Unproven bioactivity: For the sister ingredient sh-Oligopeptide-1, bioactivity of cosmetic copies has not been demonstrated (Martínez-Carpio 2023); a supplier activity assay (cell-proliferation test) is the relevant document to request.
- Cold-chain stability: Proteins degrade with heat; becaplermin gel requires refrigeration at 2–8 °C (Regranex label), so warm-stored serums may lose activity.
- Sterility: Products used with microneedling are pushed into the dermis; ariessence pure PDGF+ is a sterile formulation with hyaluronic acid (NCT07718347), whereas most serums are not sterile.
- Third-party testing: No independent testing program (ConsumerLab, USP, the US Pharmacopeia) covers cosmetic growth factors, so content claims rest on the manufacturer.
- Brands: Lynch Regenerative Medicine sponsors post-market evaluation of its clinic product ariessence pure PDGF+ (NCT07718347); Blueprint Peptide Serum lists sh-Polypeptide-59 among seven synthetic peptides (Perfect Hair Health review).
Practical Considerations
- Time to effect: Follicles cycle over months; a meta-analysis of platelet-injection trials found density gains at 3 and 6 months (Zhang 2023), so judging a growth-factor serum before 6 months is premature.
- Common pitfalls: Assuming a large protein crosses intact scalp; stacking many actives so no single effect can be judged; replacing established hair-loss drugs with an unproven cosmetic; and judging results by early shedding.
- US regulatory status: Products promoted to grow hair are new drugs requiring approval, and no OTC hair-grower ingredient is recognized as safe and effective (21 CFR 310.527); sh-Polypeptide-59 serums are sold as cosmetics.
- EU regulatory status: The EU inventory lists sh-Polypeptide-59 with a skin-conditioning function and no restrictions or expert-committee opinions (EU CosIng entry).
- Cost and payer incentives: The Blueprint serum costs $119 per 50 mL (Perfect Hair Health review). Cosmetic hair products are paid out of pocket, so no institutional payer incentive for or against them was identified.
Interaction with Foundational Habits
- Sleep: None. No study links PDGF-BB to sleep; short sleep raises stress hormones that can trigger shedding, so poor sleep may mask any effect. Evening application after showering fits most routines.
- Nutrition: Indirect. Follicles need protein, iron and zinc; deficiencies cause shedding that a growth factor cannot offset, and iron, vitamin D and B12 deficiencies are named causes of hair loss (Attia AMA #63). It depletes no nutrients.
- Exercise: None known. Heavy sweating may dilute or wash off a topical serum, so application after the post-workout shower keeps contact time; no effect on training adaptation is expected from a topical protein.
- Stress management: Indirect. Psychological stress is a named cause of hair loss (Attia AMA #63); PDGF-BB does not act on cortisol, so stress-triggered shedding needs separate attention and may confound judgment of results.
Monitoring Protocol & Defining Success
Baseline testing before starting consists of a standardized scalp photograph set (vertex, crown, part line, hairline) under fixed lighting, a dermatoscopic (magnified skin-surface imaging) hair count in a marked 1 cm² area, and a full scalp skin examination for lesions that would rule out use. Blood tests are not needed, because the protein produces no consistent rise in blood levels and has no known systemic effect. Ongoing monitoring repeats the scalp photographs and hair count at 3 months and 6 months, then every 6–12 months during continued use, with a scalp skin check at each visit and yearly dermatologist review. Success is defined as a measurable increase in hair density or shaft diameter at the marked site versus the individual’s own baseline at 6 months; no change by then marks non-response.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Hair density (hairs/cm²) | No established target; track change from own baseline at the marked site | Expected to change if the product works | Phototrichogram (computer-assisted hair count of a trimmed, marked area), e.g., TrichoScan as used in a PRP trial (Rodrigues 2019); same site, lighting and trim length each time |
| Anagen hair percentage | No established target; track change from own baseline | Expected to change: the growth-phase share should rise | Measured with the same phototrichogram after a 2–3 day regrowth interval; anagen percentage rose with PRP versus saline (Rodrigues 2019) |
| Mean hair shaft diameter | No established target; track change from own baseline | Expected to change: thicker shafts indicate follicle recovery | Dermatoscopic or phototrichogram measurement at the same site; small changes fall within measurement error |
| Scalp skin examination | No established target; any new, changing or bleeding lesion | Safety check: a lesion stops use at that site | Becaplermin is contraindicated on neoplasms at the application site (Regranex label); dermatologist review yearly |
Qualitative markers:
- Daily shedding volume (hairs on pillow, in the drain or brush)
- Visible scalp show-through on standardized photographs
- Hair volume and ease of styling
- Scalp comfort: itching, burning, redness or flaking after application
Emerging Research
- No registered hair trial: A ClinicalTrials.gov search found no registered trial of sh-Polypeptide-59 or recombinant PDGF-BB for hair loss. The hair question for health-focused adults therefore rests on mouse work and multi-factor platelet injections.
- Scalp wound matrix trial (NCT06634030): Phase 2, 36 participants, rhPDGF-BB versus saline in head and neck surgical wounds, including scalp, with Lynch Regenerative Medicine as collaborator; completed July 2026, no results posted. Positive results would support PDGF-BB activity in scalp skin repair; null results would weaken the ulcer-healing item’s relevance.
- Injected PDGF-BB for under-eye hollows (NCT07914816): Phase 2, 75 participants, saline-controlled, not yet recruiting, sponsored by Lynch Regenerative Medicine; primary outcomes are adverse events and hollow severity. A clean safety result would strengthen cosmetic-use safety; excess adverse events would weaken it.
- Ariessence after laser resurfacing (NCT07718347): 21 participants, recruiting, randomized 2:1 against standard aftercare, sponsored by the maker; outcomes include erythema and aesthetic improvement. Good tolerability would support skin-surface safety; poor tolerability would raise irritation concerns. Neither result addresses hair.
- Penetration through intact scalp: No study has shown whether a 25 kDa protein reaches follicles from a cosmetic serum; the 500-dalton rule predicts it does not (Bos 2000). Penetration data could strengthen or largely undercut the topical case.
- PDGF-AA as a rival isoform: PDGF-AA induced epiregulin that lengthened human hair shafts in culture (Jeong 2020), and a skin-penetrating PDGF-AA conjugate boosted dermal papilla cells (Shin 2025), possibly shifting interest away from the BB form.
- Standardization versus efficacy: A 2026 review found PDGF levels did not consistently track PRP outcomes and warned that a standardized PDGF-BB product is not thereby more effective (Gould 2026).
Conclusion
sh-Polypeptide-59 is a lab-made copy of a natural repair protein released by blood platelets. It is sold in scalp serums and clinic products to people seeking fuller hair, including those who see hair as part of a broader longevity effort.
The idea behind it is reasonable: in mice, this protein switches resting hair follicles into growth and supports the stem cells that rebuild them. But no study has tested the ingredient itself on human hair. The closest human evidence comes from injections of a person’s own concentrated platelets, which release this protein along with many others; these injections modestly improve hair density in most trials, yet the amount of this protein in them does not track the results. A further question is whether a protein this large can pass through unbroken scalp skin at all.
On safety, a nearly identical prescription wound gel has decades of use. It causes occasional skin redness, and an early signal of more cancer deaths in heavy users was not confirmed by later, larger studies, though the warning remains on its label. People with skin cancer on the scalp or known cancer elsewhere face the clearest concern.
The evidence base is thin and partly produced by companies that sell the protein, including the main safety review and the wound-drug studies. For a proactive adult, sh-Polypeptide-59 is a biologically plausible but untested add-on to hair care, whose value rests more on laboratory reasoning than on human results.